Momenta Pharmaceuticals, Inc. was a biotechnology company focused on the discovery, development, and commercialization of novel biologic therapeutics for rare, immune-mediated diseases. Headquartered in Cambridge, Massachusetts, Momenta was known for its expertise in understanding the structural attributes of complex molecules to develop differentiated medicines. In October 2020, Momenta Pharmaceuticals was acquired by Johnson & Johnson for approximately $6.5 billion, and its operations and pipeline were integrated into Janssen Pharmaceutical Companies of Johnson & Johnson. Prior to its acquisition, Momenta was advancing a pipeline of drug candidates in hematology, neurology, and autoimmune diseases.
The headquarters served as the primary center for research and development, corporate operations, and strategic decision-making for Momenta Pharmaceuticals before its acquisition.
Located in Kendall Square, a dense cluster of biotech and pharmaceutical companies, offering state-of-the-art laboratory and office spaces conducive to scientific innovation.
Prior to acquisition, the work culture was likely characterized by scientific rigor, innovation, collaboration, and a strong focus on developing treatments for patients with unmet medical needs, typical of a mission-driven biotech company.
Its Cambridge location was significant due to the proximity to leading academic institutions (like MIT and Harvard), research hospitals, and a rich talent pool, fostering collaborations and innovation in the life sciences sector.
Prior to its acquisition by Johnson & Johnson, Momenta Pharmaceuticals' operations were primarily based in the United States, with its headquarters in Cambridge, MA, serving as the hub for its research, development, and corporate functions. Its global reach was mainly through clinical trials conducted in various countries to support its drug development programs and through potential collaborations or partnerships. Post-acquisition, its assets and programs became part of Johnson & Johnson's extensive global R&D and commercial network.
250 First Avenue
Cambridge
MA
USA
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Momenta Pharmaceuticals' leadership includes:
Momenta Pharmaceuticals has been backed by several prominent investors over the years, including:
Following the announcement and completion of Momenta Pharmaceuticals' acquisition by Johnson & Johnson in late 2020, the existing executive team largely transitioned out of their roles at Momenta as the company was integrated into J&J. Most changes occurred around October 2020.
Discover the tools Momenta Pharmaceuticals uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Prior to its acquisition by Johnson & Johnson, Momenta Pharmaceuticals likely used a common corporate email format, such as first initial followed by last name. As the company is now part of Johnson & Johnson and the momentapharma.com domain is inactive, these email formats are no longer in use.
[first_initial][last]@momentapharma.com
Format
jdoe@momentapharma.com
Example
0%
Success rate
Johnson & Johnson • October 1, 2020
Johnson & Johnson announced it has successfully completed its acquisition of Momenta Pharmaceuticals, Inc., a company that discovers and develops novel biologic therapeutics for rare immune-mediated diseases. Momenta's stockholders approved the transaction, for which J&J paid $6.5 billion in an all-cash deal. Momenta's pipeline, including nipocalimab, will now be part of Janssen Pharmaceutical Companies....more
PR Newswire • August 19, 2020
Johnson & Johnson and Momenta Pharmaceuticals, Inc. announced they have entered into a definitive agreement for J&J to acquire Momenta for $52.50 per share in an all-cash transaction, representing a total equity value of approximately $6.5 billion. The acquisition will provide Janssen with an opportunity to broaden its leadership in immune-mediated diseases and drive further growth....more
GlobeNewswire • July 29, 2020
Momenta Pharmaceuticals reported its financial results for the second quarter ending June 30, 2020, highlighting progress in its clinical programs, including nipocalimab for multiple indications. The company also provided updates on its research pipeline and corporate activities prior to the acquisition announcement....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Momenta Pharmaceuticals, are just a search away.